Research Reference
PT-141 (Bremelanotide)
FDA-approved melanocortin agonist for HSDD (also known as PT-141)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Bremelanotide (Vyleesi) is an FDA-approved melanocortin receptor agonist for premenopausal women with hypoactive sexual desire disorder (HSDD). PT-141 refers to the same compound in grey-market contexts.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 1.75 mg | 35 units | 0.35 mL | SubQ, as needed (≥45 min pre)FDA-approved dose (Vyleesi, female) |
| 2 mg | 40 units | 0.4 mL | SubQ, as neededCommon community protocol |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, supplied as a 1.75 mg pre-filled autoinjector. Compounded research-peptide forms (10 mg or 20 mg vials) are not FDA-approved.
For a compounded 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 1.75 mg dose draws to 35 units (0.35 mL) on a U-100 syringe. For a 20 mg vial reconstituted with 4 mL, the concentration is 5 mg/mL; a 1.75 mg dose draws to 35 units (0.35 mL). Gently swirl — do not shake — and store refrigerated.
Cycling Protocol
FDA-approved bremelanotide (Vyleesi) is used as needed, at least 45 minutes before anticipated sexual activity, no more than one dose per 24 hours and no more than 8 doses per month. No continuous daily cycle is established.
Routes of Administration
Subcutaneous injection (FDA-approved route): Into the abdomen or thigh, as needed.
Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | PT-141 alone | Bremelanotide | FDA-approved HSDD protocol | | Tanning/Libido | Bremelanotide + Melanotan II (community) | Combined melanocortin effects (community, not established) |
Combining melanocortin agonists is not established. Bremelanotide (compounded) is not FDA-approved except as Vyleesi.
Side Effects & Safety
- Nausea — most common, sometimes significant
- Flushing — common
- Injection-site reactions — common
- Transient blood pressure increase — common; monitor in CV disease
- Skin hyperpigmentation — possible (MC1R agonism)
- Headache — common
Bremelanotide (Vyleesi) is FDA-approved for premenopausal HSDD. Compounded research-peptide forms are not FDA-approved.
Research Basis
Bremelanotide (PT-141) is a melanocortin receptor agonist (heptapeptide derived from melanotan II), FDA-approved as Vyleesi.
Mechanism: Agonizes melanocortin receptors (MC1R, MC3R, MC4R) in the CNS, with the pro-sexual effect attributed to MC4R-mediated activation of central arousal pathways (distinct from melanotan II's primary MC1R tanning effect).
Clinical evidence: FDA-approved (2019) for acquired, generalized HSDD in premenopausal women; demonstrated increased satisfying sexual events and desire. An earlier intranasal formulation was discontinued.
FDA-approved (Vyleesi) for premenopausal HSDD. Compounded research-peptide forms are not FDA-approved.